HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.
HDT Bio has raised $5.2M in total funding. The most recent round was Grant. The last funding was announced in September 2026.
HDT Bio's investors include Advanced Research Projects Agency for Health, National Institutes of Health, Zoic Capital, National Institute of Allergy and Infectious Diseases, US Army.
HDT Bio is headquartered in Seattle, United States.
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.
HDT Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HDT Bio — Funding & Investors." VCBacked, September 15, 2026, https://www.vcbacked.co/company/hdt-bio. Accessed October 19, 2026.
VCBacked. (2026). HDT Bio — Funding & Investors. Retrieved October 19, 2026, from https://www.vcbacked.co/company/hdt-bio
{{cite web |title=HDT Bio — Funding & Investors |url=https://www.vcbacked.co/company/hdt-bio |website=VCBacked |access-date=October 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated